Advanced Heart Failure and Mechanical Circulatory Support
Defining advanced HF
Advanced HF means persistent NYHA III–IV symptoms despite optimized therapy, recurrent hospitalizations, intolerance of GDMT, and end-organ dysfunction. Objective markers include peak VO2 <12–14 mL/kg/min, inotrope dependence, and INTERMACS profiles 1–4. Refer for advanced therapies before irreversible end-organ damage-early referral is the key quality metric.
Temporary and durable support
In cardiogenic shock, use SCAI stages to guide escalation. IABP modestly improves coronary perfusion but adds little cardiac output; Impella unloads the LV; VA-ECMO provides full circulatory support but raises afterload and can cause LV distension, often requiring venting. Durable LVAD (HeartMate 3) is indicated for NYHA IIIB–IV patients with LVEF ≤25% who are inotrope-dependent or have recurrent admissions and are not transplant candidates, or as a bridge. Complications include bleeding (especially GI angiodysplasia), pump thrombosis, stroke, driveline infection, aortic insufficiency, and right heart failure.
Traps
LVAD patients may have no palpable pulse-measure BP with Doppler and target MAP ~70–80 mmHg. Anticoagulation is warfarin plus aspirin, not a DOAC. Echocardiography guides speed optimization and aortic valve opening. Do not attribute shock to LV failure alone without assessing the right ventricle.
Worked example
A 60-year-old on milrinone with worsening renal function, INTERMACS 3, and no transplant contraindication should be evaluated for durable LVAD versus transplant. Rule of thumb: inotrope dependence defines advanced HF-refer while organs are still recoverable.